Fair Isaac Corporation (FICO) is rated as a Hold due to regulatory risks that threaten its pricing power and volume in mortgage credit scoring. While Q4 FY2026 showed strong free cash flow, much of it came from mortgage price hikes that may not be sustainable. The current valuation only partially reflects these risks, and further downside is possible if mortgage volumes decline or regulatory changes accelerate. The lack of guidance for FY2027 and ongoing regulatory uncertainty keep investor confidence low, suggesting the stock may remain range-bound with downside risks prevailing.
Fair Isaac Corporation's stock situation is presented here with Pluang's Financials sector data as context. Of 142 priced Financials-sector US stocks on Pluang, 51 rose and 91 fell today. Notable movers include LMND at USD 39.55 with a 1-day change of -4.65%, ALL at USD 254.81 with 0% Sell / 100% Buy order activity, and DB at USD 34.84 with a 1-day change of -4.34%, as of Nov 07, 2026 21:21 WIB.
Shiba Inu (SHIB) closed October at $0.00000468, down 18.7% for the month and 53.3% from November 1, 2025. In Germany, the one-year holding period for tax-free sales expires on November 2, 2026, meaning losses on SHIB bought on November 1, 2025, can n...
The XRP Ledger Foundation has outlined 24 proposed and approved protocol upgrades for 2027, estimating implementation costs up to $5.74 million excluding development labor. Key features include collateralized lending, perpetual futures, smart contrac...
China's central bank declared Solana's promotion in Shanghai illegal, halting the Solana Accelerate China 2026 tour and investigating involved Chinese service providers. Despite this, Solana's price remains steady around $90, just above its 200-day m...
Shares of Taiwan Semiconductor Manufacturing Company (TSMC) rose 6.26% after reports that it might begin producing vertically stacked DRAM memory chips for Nvidia, its top customer. Neither company has confirmed the plans, and TSMC has not announced ...
Johnson & Johnson announced positive Phase 3 trial results for ICOTYDE (icotrokinra), an oral peptide targeting IL-23R, in treating biologic-naïve adults with active psoriatic arthritis. At 16 weeks, 58% of patients achieved ACR20 response versus 41%...
